Hongkong XinRunde Chemical Co., Ltd

 

Reliable Manufacturer and Supplier of Top Quality Pharmaceutical Raw Material and Pharmaceutical Intermediate

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsPharmaceutical Raw Material

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight
99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

Large Image :  99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight Get Best Price

Product Details:
Place of Origin: China
Brand Name: XRD
Certification: GMP
Model Number: 96829-58-2
Payment & Shipping Terms:
Minimum Order Quantity: negotiable
Price: Inquiry for Negotiable
Packaging Details: 1-2 kg / aluminum foil bag, 25kg/ drum, as required
Delivery Time: 1-2days after payment received
Payment Terms: T/T bank, Western Union, Bitcoin, Etc
Supply Ability: 1000KG/ Month
Detailed Product Description
CAS: 96829-58-2 Product Name: Orlistat
Type: Pharmaceutical Raw Material Appearance: White Powder
Usage: For Loss Weight Alias: Orlipastat ,XENICAL
Assay: 99% Key Words: Orlistat
High Light:

pharm raw material

,

research chemicals

 

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

 

1. Basic Info

 

Product Name: Orlistat
Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;XENICAL;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat
CAS: 96829-58-2
MF: C29H53NO5
MW: 495.73
EINECS: 639-755-1
Product Categories: Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;-;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight
Mol File: 96829-58-2.mol
Orlistat Structure

 

2. Descriptions:

 

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.

 

 

3. Applications:

 

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.

The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

 

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. The effectiveness of orlistat in promoting weight loss is definite, Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

 

The effectiveness of orlistat in promoting weight loss is clear, albeit moderately. The pooled data from clinical trials show that people who give olivide have less than 2-3 kilograms (4.4-6.6 pounds) of medication than a year, except for changes in lifestyle such as diet and exercise. Is also a modest reduction in blood pressure, it seems to be able to prevent the onset of type 2 diabetes, whether due to weight loss itself or other effects; in a large randomized controlled trial, orlistat he was found in obese people will reduce the incidence of diabetes by nearly 40%

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

 

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight 1

 

4. Orlistat COA

 

tems Specification Items Result
Appearance white or almost white crystalline powder,smell less White crystalline powder
Melting Point 42.0~46.0°C Confirmed
Specific Rotation -31°~-39°(CHCl3,C=1) Confirmed
Identification The result of HPLC is consisitent to the reference one. The result of IR is consisitent to the reference one. Confirmed
Related Substances ≤ 0.5% ≤ 0.05%
Total impurity ≤ 1.0% Confirmed
Single impurity ≤ 0.1% Confirmed
  ≤ 290ppm Confirmed
  ≤ 5000ppm Confirmed
Residual on Ignition ≤0.1% Confirmed
Sulphate ≤ 0.05% Confirmed
Heavy Metal ≤ 20ppm Confirmed
Purity ≤ 99.0% ~ 99.9% Confirmed
 

 

 

 

99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight

 

Contact Details
Hongkong XinRunde Chemical Co., Ltd

Contact Person: Mr. Bruce Lee

Tel: +8618874586545

Fax: 86-27-8321-4688

Send your inquiry directly to us